These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 3335729)

  • 21. Oxybutynin chloride for geriatric urinary dysfunction: a double-blind placebo-controlled study.
    Zorzitto ML; Holliday PJ; Jewett MA; Herschorn S; Fernie GR
    Age Ageing; 1989 May; 18(3):195-200. PubMed ID: 2675580
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimum Dose of Once-Daily Oxybutynin Patch in Japanese Patients with Overactive Bladder: A Randomized Double-Blind Trial Versus Placebo.
    Yamaguchi O; Uchida E; Higo N; Minami H; Kobayashi S; Sato H;
    Low Urin Tract Symptoms; 2016 Sep; 8(3):150-8. PubMed ID: 27619779
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase 2, randomized, double-blind, efficacy and safety study of oxybutynin vaginal ring for alleviation of overactive bladder symptoms in women.
    Gittelman M; Weiss H; Seidman L
    J Urol; 2014 Apr; 191(4):1014-21. PubMed ID: 24231837
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multi-center randomized controlled trial of cognitive treatment, placebo, oxybutynin, bladder training, and pelvic floor training in children with functional urinary incontinence.
    van Gool JD; de Jong TP; Winkler-Seinstra P; Tamminen-Möbius T; Lax H; Hirche H; Nijman RJ; Hjälmås K; Jodal U; Bachmann H; Hoebeke P; Walle JV; Misselwitz J; John U; Bael A;
    Neurourol Urodyn; 2014 Jun; 33(5):482-7. PubMed ID: 23775924
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical efficacy of oxybutynin on sensory urgency as compared with that on motor urgency.
    Hashimoto K; Ohnishi N; Esa A; Sugiyama T; Park Y; Kurita T
    Urol Int; 1999; 62(1):12-6. PubMed ID: 10436424
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Does eradicating bacteriuria affect the severity of chronic urinary incontinence in nursing home residents?
    Ouslander JG; Schapira M; Schnelle JF; Uman G; Fingold S; Tuico E; Nigam JG
    Ann Intern Med; 1995 May; 122(10):749-54. PubMed ID: 7717597
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An extended-release formulation of oxybutynin chloride for the treatment of overactive urinary bladder.
    Goldenberg MM
    Clin Ther; 1999 Apr; 21(4):634-42. PubMed ID: 10363730
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tolterodine: a clinical review.
    Crandall C
    J Womens Health Gend Based Med; 2001 Oct; 10(8):735-43. PubMed ID: 11703885
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Which anticholinergic drug for overactive bladder symptoms in adults.
    Hay-Smith J; Herbison P; Ellis G; Morris A
    Cochrane Database Syst Rev; 2005 Jul; (3):CD005429. PubMed ID: 16034974
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of prompted voiding on fecal continence among nursing home residents.
    Ouslander JG; Simmons S; Schnelle J; Uman G; Fingold S
    J Am Geriatr Soc; 1996 Apr; 44(4):424-8. PubMed ID: 8636590
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder.
    Haab F; Stewart L; Dwyer P
    Eur Urol; 2004 Apr; 45(4):420-9; discussion 429. PubMed ID: 15041104
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Instability of the detrusor muscle. Treatment with oxybutynin chloride (ditropan)].
    Perales Cabanas L; Tallada Buñuel M; Romero Maroto J; Escribano Patiño G
    Actas Urol Esp; 1986; 10(6):481-6. PubMed ID: 3825651
    [No Abstract]   [Full Text] [Related]  

  • 33. Preliminary evaluation of a new controlled-release oxybutynin in urinary incontinence.
    Radomski SB; Caley B; Reiz JL; Miceli PC; Harsanyi Z; Darke AC
    Curr Med Res Opin; 2004; 20(2):249-53. PubMed ID: 15006020
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder.
    Cardozo L; Lisec M; Millard R; van Vierssen Trip O; Kuzmin I; Drogendijk TE; Huang M; Ridder AM
    J Urol; 2004 Nov; 172(5 Pt 1):1919-24. PubMed ID: 15540755
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo.
    Thüroff JW; Bunke B; Ebner A; Faber P; de Geeter P; Hannappel J; Heidler H; Madersbacher H; Melchior H; Schäfer W
    J Urol; 1991 Apr; 145(4):813-6; discussion 816-7. PubMed ID: 2005707
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of oral estrogen and progestin on the lower urinary tract among female nursing home residents.
    Ouslander JG; Greendale GA; Uman G; Lee C; Paul W; Schnelle J
    J Am Geriatr Soc; 2001 Jun; 49(6):803-7. PubMed ID: 11454122
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity.
    Ginsberg D; Gousse A; Keppenne V; Sievert KD; Thompson C; Lam W; Brin MF; Jenkins B; Haag-Molkenteller C
    J Urol; 2012 Jun; 187(6):2131-9. PubMed ID: 22503020
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics, efficacy, and safety of intravesical formulation of oxybutynin in patients with detrusor overactivity.
    Lehtoranta K; Tainio H; Lukkari-Lax E; Hakonen T; Tammela TL
    Scand J Urol Nephrol; 2002 Feb; 36(1):18-24. PubMed ID: 12002352
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study.
    Schurch B; de Sèze M; Denys P; Chartier-Kastler E; Haab F; Everaert K; Plante P; Perrouin-Verbe B; Kumar C; Fraczek S; Brin MF;
    J Urol; 2005 Jul; 174(1):196-200. PubMed ID: 15947626
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of controlled-release oxybutynin on neurogenic bladder function in spinal cord injury.
    O'Leary M; Erickson JR; Smith CP; McDermott C; Horton J; Chancellor MB
    J Spinal Cord Med; 2003; 26(2):159-62. PubMed ID: 12828295
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.